WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies USA

Published on :

WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based in St. Louis and San Diego, today announced a partnership to produce Wugen’s WU-NK-101, a novel immunotherapy that harnesses the power of memory natural killer (NK) cells to treat cancers. WuXi ATU will provide manufacturing and testing services for WU-NK-101 to enable the delivery of this innovative cell therapy product to cancer patients.

Sirnaomics Announces Publication of STP705 Clinical Study Results for Treatment of isSCC in the Peer-Reviewed Journal of Drugs in Dermatology

Published on :

Sirnaomics Ltd. (“Sirnaomics”, stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the peer-reviewed publication of Phase IIa clinical study results of its lead therapeutic candidate, STP705, for the treatment of skin cancer, in the May 2022 issue of the Journal of Drugs in Dermatology (the “JDD”). The study, titled “Safety and Efficacy of TGF-β1/COX-2 Silencing Therapeutic in Adults with Cutaneous Squamous Cell Carcinoma In Situ,” showed that STP705 was safe and well-tolerated in patients with Cutaneous Squamous Cell Carcinoma In Situ (isSCC).

PQE US Inc., part of PQE Group, recognized as a Great Place to Work®

Published on :

With steadfast listening and support, well-structured corporate benefit plans, and broad flexibility, PQE maintains a continuous dialogue with its employees. As a result, PQE Group, among the leading international consulting firms in the pharma world, has achieved recognition in the United States by Great Place to Work®, the world authority on workplace culture. After analyzing the feedback of U.S. employees and after collecting HR policies, the organization declared that the PQE USA Affiliate is an excellent work environment “where employees believe in the people they work for, take pride in what they do, and are comfortable with the people they work with.”

Shimadzu Scientific Instruments Extends HQ Campus with Building Acquisition

Published on :

Shimadzu Scientific Instruments (SSI) is pleased to announce the next phase in their planned expansion with the procurement of additional facilities at their headquarters in Columbia, Maryland. The purchase of a new two-story building has been finalized, bringing the campus to a total of three separate properties.

Verismo Therapeutics Announces Research Partnership with the University of Pennsylvania

Published on :

Verismo Therapeutics, a recent University of Pennsylvania spin-out company behind the novel KIR-CAR platform technology for CAR T-cells, today announces that Penn and Verismo entered into a Sponsored Research Agreement (SRA). Under the SRA, Verismo is funding additional KIR-CAR T-cell focused preclinical research programs at Penn to advance new potential treatment options for solid tumor indications. The research funded under the SRA is expected to be conducted over four years, from 2021 to 2025, in the Penn laboratories of Michael C. Milone, MD, PhD, an associate professor of Pathology and Laboratory Medicine, and Donald L. Siegel, MD, PhD, a professor of Pathology and Laboratory Medicine.

Theradaptive Secures Third FDA Breakthrough Designation for Spinal Fusion

Theradaptive Logo
Published on :

Theradaptive, a privately held biopharmaceutical company pioneering a new class of regenerative implants announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Medical Device designation for the use of OsteoAdapt SP in Anterior Lumbar Interbody Fusion. This is the third Breakthrough Designation for Theradaptive in spinal fusion, along with transforaminal interbody and posterolateral fusion, allowing it to address over 90% of lumbar spinal fusion procedures.

Arcellx Announces Closing Of Upsized Public Offering Of Common Stock And Underwriters’ Full Exercise Of Option To Purchase Additional Shares

Published on :

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the closing of its upsized public offering of 8,050,000 shares of common stock, which includes the full exercise by the underwriters of their option to purchase an additional 1,050,000 shares of common stock, at a price to the public of $16.00 per share. The aggregate gross proceeds raised in the offering were $128.8 million, before deducting underwriting discounts and commissions and offering expenses, payable by Arcellx. All shares in the offering were offered by Arcellx.

Kemp Proteins Secures $5M Growth Financing from BroadOak Capital Partners

Published on :

Kemp Proteins, a leading CDMO specializing in the production and characterization of novel proteins, from mammalian, insect, and bacterial host cells, for the pharmaceutical, diagnostics, and research industries, announced today that it has secured financing from BroadOak Capital Partners, LLC (“BroadOak”). The transaction with BroadOak provides Kemp Proteins with capital to expand its bacteria expression and plasmid production services in Frederick, MD.

Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’

Published on :

Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals, and vaccines, today announced that the Philadelphia Business Journal named the Company among the “2022 Best Places to Work.”

Center for Breakthrough Medicines Accelerates Plans to Build the Largest Cell Therapy Manufacturing Operation in the World

Published on :

The Center for Breakthrough Medicines (CBM) in partnership with the Discovery Labs announced today the acceleration of plans to build capacity to manufacture more than 10,000 patient therapies in direct response to the critical shortage of cell therapy supply, which will help patients win their courageous battles against cancer.